doxorubicin hydrochloride / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   643 Trials   643 Trials   26774 News 


«12...461462463464465466467468469470471...522523»
  • ||||||||||  Rova-T (rovalpituzumab tesirine) / AbbVie, BMS
    Review, Journal:  Treatment advances in small cell lung cancer (SCLC). (Pubmed Central) -  Jul 8, 2018   
    There have been no recent changes in the treatment of SCLC, with platinum plus etoposide and topotecan as the standard first-line and second-line respectively, neither showing survival benefit over the combination of cyclophosphamide, doxorubicin and vincristine, which was developed in the 1970s. More recently, a new understanding of the biology of SCLC has led to the development of novel drugs, of which the most promising are the immune checkpoint inhibitors and the antibody drug conjugate rovalpituzumab tesirine.
  • ||||||||||  cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    New P2 trial:  Evaluation of Ocoxin (clinicaltrials.gov) -  Jul 2, 2018   
    P2,  N=120, Completed, 
  • ||||||||||  Trial completion date, Trial primary completion date, Metastases:  High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer (clinicaltrials.gov) -  Jul 2, 2018   
    P3,  N=74, Recruiting, 
    Trial completion date: Jul 2024 --> Mar 2023 | Trial primary completion date: Jun 2021 --> Jul 2018 Trial completion date: Jul 2021 --> Oct 2020 | Trial primary completion date: Jul 2020 --> Oct 2019
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Trial completion date, Trial primary completion date, Combination therapy:  RELPALL: Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) -  Jun 25, 2018   
    P1,  N=40, Recruiting, 
    Trial completion date: May 2021 --> Aug 2021 | Trial primary completion date: May 2021 --> Aug 2021 Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Sep 2020 --> Sep 2021
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Journal:  Targeting nano drug delivery to cancer cells using tunable, multi-layer, silver-decorated gold nanorods. (Pubmed Central) -  Jun 24, 2018   
    Furthermore, these nanoparticles have a unique spectral signature by surface enhanced Raman spectroscopy (SERS), which enables reliable detection and monitoring of the distribution of these chemotherapy constructs inside cells. The development of interest in a plasmonic nano drugs system with unique spectroscopic signatures could result in a clinical approach to the precise targeting and visualization of cells and solid tumors while delivering molecules for the enhanced treatment of cancerous tumors.
  • ||||||||||  cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Journal:  Expression and Therapeutic Potential of SOX9 in Chordoma. (Pubmed Central) -  Jun 22, 2018   
    Our results demonstrate that SOX9 plays a crucial role in chordoma. Targeting SOX9 provides a new rationale for treatment of chordoma.
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date, Surgery:  AREN0534: Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor (clinicaltrials.gov) -  Jun 21, 2018   
    P3,  N=249, Completed, 
    Targeting SOX9 provides a new rationale for treatment of chordoma. Active, not recruiting --> Completed | Trial completion date: Oct 2018 --> Jun 2017 | Trial primary completion date: Oct 2018 --> Jun 2017
  • ||||||||||  Trial completion date, Trial primary completion date, Metastases:  High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer (clinicaltrials.gov) -  Jun 18, 2018   
    P3,  N=74, Recruiting, 
    N=22 --> 29 | Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Apr 2019 --> Jul 2020 Trial completion date: Jul 2019 --> Jul 2021 | Trial primary completion date: Jul 2018 --> Jul 2020
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial completion date, Combination therapy:  A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma (clinicaltrials.gov) -  Jun 14, 2018   
    P2,  N=43, Active, not recruiting, 
    Trial completion date: Apr 2019 --> Apr 2020 | Trial primary completion date: Jun 2018 --> Jun 2019 Trial completion date: Apr 2018 --> May 2019
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Trial completion date, Trial primary completion date:  R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma (clinicaltrials.gov) -  Jun 14, 2018   
    P3,  N=336, Active, not recruiting, 
    Trial completion date: Apr 2018 --> May 2019 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Feb 2018 --> Feb 2019
  • ||||||||||  everolimus / Generic mfg.
    Trial completion date, Trial primary completion date:  EVACEL: Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors (clinicaltrials.gov) -  Jun 13, 2018   
    P2,  N=74, Active, not recruiting, 
    Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Feb 2018 --> Feb 2019 Trial completion date: Apr 2017 --> Apr 2019 | Trial primary completion date: Apr 2017 --> Sep 2018
  • ||||||||||  dacarbazine / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Clinical, Journal:  Pruritic Rash in a Patient with Hodgkin's Lymphoma. (Pubmed Central) -  Jun 12, 2018   
    This benign condition is important to recognize to avoid potentially unnecessary and harmful treatment for other dermatologic diagnoses for which it may be mistaken. In severe cases of FE, discontinuation of bleomycin should be considered.
  • ||||||||||  Adcetris (brentuximab vedotin) / Takeda, Pfizer
    Trial completion, Trial completion date, Trial primary completion date:  Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma (clinicaltrials.gov) -  Jun 12, 2018   
    P2,  N=34, Completed, 
    In severe cases of FE, discontinuation of bleomycin should be considered. Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Jun 2018 | Trial primary completion date: Apr 2019 --> Jun 2018
  • ||||||||||  Trial completion date, Trial primary completion date:  High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) (clinicaltrials.gov) -  Jun 11, 2018   
    P3,  N=3300, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Sep 2017 --> Sep 2024 | Trial primary completion date: Sep 2017 --> Nov 2019
  • ||||||||||  ifosfamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., vincristine / Generic mfg.
    Clinical, Journal:  Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. (Pubmed Central) -  Jun 9, 2018   
    We modeled our treatment on other adult sarcomas and reviewed the charts of 71 adult patients with ES treated with vincristine, ifosfamide, and doxorubicin (VID). In adults with primary ES, VID combined with an adjuvant strategy based on post-treatment percent necrosis has favorable outcomes compared with historical adult controls.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Clinical, Journal:  Phenotyping and Visualizing Infusion-Related Reactions for Breast Cancer Patients. (Pubmed Central) -  Jun 7, 2018   
    Using the algorithm, an incidence of 6.4% of patients and 1.8% of doses for docetaxel, 8.7% and 3.2% for doxorubicin, 10.4% and 1.2% for paclitaxel, 16.1% and 1.1% for trastuzumab were identified retrospectively. The incidences estimated are consistent with related studies.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Journal:  Triple-negative breast cancer targeting and killing by EpCAM-directed, plasmonically active nanodrug systems. (Pubmed Central) -  Jun 7, 2018   
    Here, we engineered a nanodrug delivery system consisting of silver-coated gold nanorods (AuNR/Ag) targeting epithelial cell adhesion/activating molecule (EpCAM) and loaded with doxorubicin...Analysis by these imaging detection techniques as well as by inductively coupled plasma mass spectrometry showed that the targeted nanodrug system was taken up by EpCAM-expressing cells and tumors at significantly higher rates than untargeted nanoparticles (p < 0.05). Thus, this approach establishes a plasmonically active nanodrug theranostic for triple-negative breast cancer and, potentially, a delivery platform with improved multimodal imaging capability for other clinically relevant chemotherapeutics with dose-limiting toxicities, such as platinum-based or taxane-based therapies.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Trial completion date, Trial primary completion date:  Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen (clinicaltrials.gov) -  Jun 6, 2018   
    P4,  N=109, Recruiting, 
    N=18 --> 0 Trial completion date: Dec 2021 --> Dec 2020 | Trial primary completion date: Dec 2021 --> Dec 2020